FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  	OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Jaen Juan C.	2. Issuer Name and Ticker or Trading Symbol

Arcus Biosciences, Inc. [ RCUS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President	
(Last)          (First)          (Middle)

C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY	3. Date of Earliest Transaction (MM/DD/YYYY)

3/19/2018		
(Street)

HAYWARD, CA 94545
(City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)

 	6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1.Title of Security
(Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code
(Instr. 8)	4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price				
Common Stock  	3/19/2018  	 	C	  	2175150   (1)	A	  (2)	2667574  	I  	By Trust  	
Common Stock  	3/19/2018  	 	P	  	66666   (3)	A	$15.00  	2734240  	I  	By Trust  	
Common Stock  	 	 	 	  	 	 	 	189393   (4)	D  	 	

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code
(Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)	8. Price of Derivative Security
(Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Series A Convertible Preferred Stock  	  (2)	3/19/2018  	 	C  	  	  	2020202   	  (2)	  (2)	Common Stock  	2020202  	  (2)	0  	I  	By Trust  	
Series B Convertible Preferred Stock  	  (2)	3/19/2018  	 	C  	  	  	125012   	  (2)	  (2)	Common Stock  	125012  	  (2)	0  	I  	By Trust  	
Series C Convertible Preferred Stock  	  (2)	3/19/2018  	 	C  	  	  	29936   	  (2)	  (2)	Common Stock  	29936   (5)	  (2)	0  	I  	By Trust  	

Explanation of Responses:	
(1) 	The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.	
(2) 	The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.	
(3) 	Represents shares purchased in the Issuer's initial public offering.	
(4) 	The total includes 126,262 shares of Common Stock acquired by the Reporting Person on January 17, 2018 for $5.39 per share pursuant to the exercise of an option granted on January 4, 2018.	
(5) 	Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Jaen Juan C.
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD, CA 94545	X		President		

Signatures		
/s/ Scott Paraker, Attorney-in-Fact		3/19/2018	
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.